Respiratory syncytial virus-induced chemokine production: Linking viral replication to chemokine production in vitro and in vivo

Journal of Infectious Diseases

Volumn 189, Issue 8, 2004, Pages 1419-1430

  Miller, Allison L ^a   Bowlin, Terry L ^b   Lukacs, Nicholas W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MICROBIOTIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; KERATINOCYTE CYTOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P10; RANTES; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; ULTRAVIOLET RADIATION; UPREGULATION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CHEMOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; HUMANS; LIPIDS; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; N-ACETYLNEURAMINIC ACID; POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RIBAVIRIN; RNA, VIRAL; UP-REGULATION; VIRION; VIRUS REPLICATION;

EID: 2142808245     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/382958     Document Type: Article

References (48)

1. Hall CB. Respiratory syncytial virus. Philadelphia: Lippincott Williams and Wilkins, 1998.
2. Lugo RA, Nahata MC. Pathogenesis and treatment of bronchiolitis. Clin Pharm 1993; 12:95-116.
3. Panitch HB. Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction. Pediatr Infect Dis J 2003; 22(Suppl 2):S83-7; discussion S87-8.
4. Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003; 48:209-33.
5. Noah TL, Ivins SS, Murphy P, Kazachkova I, Moats-Staats B, Henderson FW. Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis. Clin Immunol 2002; 104:86-95.
6. Noah TL, Becker S. Chemokines in nasal secretions of normal adults experimentally infected with respiratory syncytial virus. Clin Immunol 2000; 97:43-9.
7. Bonville CA, Rosenberg HF, Domachowske JB. Macrophage inflammatory protein-1α and RANTES are present in nasal secretions during ongoing upper respiratory tract infection. Pediatr Allergy Immunol 1999; 10:39-44.
8. Sheeran P, Jafri H, Carubelli C, et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J 1999; 18:115-22.
9. Hornsleth A, Loland L, Larsen LB. Cytokines and Chemokines in respiratory secretion and severity of disease in infants with respiratory syncytial virus (RSV) infection. J Clin Virol 2001; 21:163-70.
10. Smyth RL, Mobbs KJ, O'Hea U, Ashby D, Hart CA. Respiratory syncytial virus bronchiolitis: disease severity, interleukin-8, and virus genotype. Pediatr Pulmonol 2002; 33:339-46.
11. Jafri HS. Role of chemokines in respiratory syncytial virus disease. Pediatr Infect Dis J 2002; 21:454-6.
12. Rollins BJ. Chemokines. Blood 1997; 90:909-28.
13. Colletti LM, Green M, Burdick MD, Kunkel SL, Strieter RM. Proliferative effects of CXC chemokines in rat hepatocytes in vitro and in vivo. Shock 1998; 10:248-57.
14. Keane MP, Arenberg DA, Moore BB, Addison CL, Strieter RM. CXC chemokines and angiogenesis/angiostasis. Proc Assoc Am Physicians 1998; 110:288-96.
15. Cowell RM, Silverstein FS. Developmental changes in the expression of chemokine receptor CCR1 in the rat cerebellum. J Comp Neurol 2003; 457:7-23.
16. Miller AL, Strieter RM, Gruber AD, Ho SB, Lukacs NW. CXCR2 regulates respiratory syncytial virus-induced airway hyperreactivity and mucus overproduction. J Immunol 2003; 170:3348-56.
17. Zhang Y, Luxon BA, Casola A, Garofalo RP, Jamaluddin M, Brasier AR. Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays. J Virol 2001; 75:9044-58.
18. Saito T, Deskin RW, Casola A, et al. Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. J Infect Dis 1997; 175:497-504.
19. Olszewska-Pazdrak B, Casola A, Saito T, et al. Cell-specific expression of RANTES, MCP-1, and MIP-1α by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol 1998; 72: 4756-64.
20. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med 1999; 159:1918-24.
21. Haeberle HA, Kuziel WA, Dieterich HJ, Casola A, Gatalica Z, Garofalo RP. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1α in lung pathology. J Virol 2001; 75:878-90.
22. Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy JY, Nguyen TN. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. J Virol 2001; 75:12421-30.
23. Jafri HS. Treatment of respiratory syncytial virus: antiviral therapies. Pediatr Infect Dis J 2003; 22(Suppl 2):S89-92; discussion S92-3.
24. Kimura K, Mori S, Tomita K, et al. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res 2000; 47:41-51.
25. Kaneko H, Kato K, Mori S, Shigeta S. Antiviral activity of NMSO3 against adenovirus in vitro. Antiviral Res 2001; 52:281-8.
26. Takahashi K, Ohashi K, Abe Y, et al. Protective efficacy of a sulfated sialyl lipid (NMSO3) against human rotavirus-induced diarrhea in a mouse model. Antimicrob Agents Chemother 2002; 46:420-4.
27. Burdick MD, Kunkel SL, Lincoln PM, Wilke CA, Strieter RM. Specific ELISAs for the detection of human macrophage inflammatory protein-1 alpha and beta. Immunol Invest 1993; 22:441-9.
28. Tekkanat KK, Maassab HF, Cho DS, et al. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol 2001; 166:3542-8.
29. Sarmiento RE, Tirado R, Gomez B. Characteristics of a respiratory syncytial virus persistently infected macrophage-like culture. Virus Res 2002; 84:45-58.
30. Hegele RG, Hayashi S, Bramley AM, Hogg JC. Persistence of respiratory syncytial virus genome and protein after acute bronchiolitis in guinea pigs. Chest 1994; 105:1848-54.
31. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 2003; 22(Suppl 2):S6-10; discussion S10-2.
32. Panuska JR, Cirino NM, Midulla F, Despot JE, McFadden ER Jr, Huang YT. Productive infection of isolated human alveolar macrophages by respiratory syncytial virus. J Clin Invest 1990; 86:113-9.
33. Dakhama A, Kaan PM, Hegele RG. Permissiveness of guinea pig alveolar macrophage subpopulations to acute respiratory syncytial virus infection in vitro. Chest 1998; 114:1681-8.
34. Yui I, Hoshi A, Shigeta Y, Takami T, Nakayama T. Detection of human respiratory syncytial virus sequences in peripheral blood mononuclear cells. J Med Virol 2003; 70:481-9.
35. Rohwedder A, Keminer O, Forster J, Schneider K, Schneider E, Werchau H. Detection of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction. J Med Virol 1998; 54:320-7.
36. O'Donnell DR, McGarvey MJ, Tully JM, Balfour-Lynn IM, Openshaw PJ. Respiratory syncytial virus RNA in cells from the peripheral blood during acute infection. J Pediatr 1998; 133:272-4.
37. Bramley AM, Vitalis TZ, Wiggs BR, Hegele RG. Effects of respiratory syncytial virus persistence on airway responsiveness and inflammation in guinea-pigs. Eur Respir J 1999; 14:1061-7.
38. Tekkanat KK, Maassab H, Miller A, et al. RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease. Eur J Immunol 2002; 32:3276-84.
39. Rodriguez WJ. Contemporary diagnosis and management of respiratory syncytial virus. Newtown: Handbooks in Health Care, 2000.
40. Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983; 72:613-8.
41. Conrad DA, Christenson JC, Waner JL, Marks MI. Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic. Pediatr Infect Dis J 1987; 6:152-8.
42. Kawana F, Shigeta S, Hosoya M, Suzuki H, De Clercq E. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother 1987; 31:1225-30.
43. Fiedler MA, Wernke-Dollries K, Stark JM. Inhibition of viral replication reverses respiratory syncytial virus-induced NF-κB activation and interleukin-8 gene expression in A549 cells. J Virol 1996; 70:9079-82.
44. Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003; 77:5933-47.
45. Hegele RG, Robinson PJ, Gonzalez S, Hogg JC. Production of acute bronchiolitis in guinea-pigs by human respiratory syncytial virus. Eur Respir J 1993; 6:1324-31.
46. Haeberle HA, Takizawa R, Casola A, et al. Respiratory syncytial virus-induced activation of nuclear factor-κB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis 2002; 186:1199-206.
47. Becker S, Quay J, Soukup J. Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol 1991; 147:4307-12.
48. Stadnyk AW, Gillan TL, Anderson R. Respiratory syncytial virus triggers synthesis of IL-6 in BALB/c mouse alveolar macrophages in the absence of virus replication. Cell Immunol 1997; 176:122-6.